Dergiler / Turkish Journal of Gastroenterology / 2018 / Cilt: 29 - Sayı: 2

Combined treatment for gastric cancer: Immunological approach

Sayfa
151–156
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Of the 62 patients involved in our study, 32 underwent neoadjuvant chemotherapy in combination with surgery, whereas the rest underwent neoadjuvant chemoimmunotherapy with surgery.Results: Investigation of T-cell-mediated and humoral immunity in patients with gastric cancer over the course of treatment found a reduction of the main indices of cell-mediated and humoral immunity in the patients who underwent standard therapy, which greatly caused a decline of antitumor, anti-infective, and antitoxic protection of the patients’ organisms.Conclusion: This study can contribute to the development of new therapies for gastric cancer as well as other types of cancer.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Gastric cancer is one of the most common oncological diseases.
📊
Temel Bulgular & Veri:It can develop in any part of the stomach and spread to other organs, especially the esophagus, lungs, and liver.
💡
Sonuç & Katkı:Of the 62 patients involved in our study, 32 underwent neoadjuvant chemotherapy in combination with surgery, whereas the rest underwent neoadjuvant chemoimmunotherapy with surgery.Results: Investigation of T-cell-mediated and humoral immunity in patients with gastric cancer over the course of treatment found a reduction of the main indices of cell-mediated and humoral immunity in the patients who underwent standard therapy, which greatly caused a decline of antitumor, anti-infective, and antitoxic protection of the patients’ organisms.Conclusion: This study can contribute to the development of new therapies for gastric cancer as well as other types of cancer.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Gastric cancer is one of the most common oncological diseases. It can develop in any part of the stomach and spread to other organs, especially the esophagus, lungs, and liver. The aim of our study was to investigate the effectiveness of our pro-posed therapy.Materials and Methods: Our research promises more effective neoadjuvant therapy, including immunotherapy and multi-agent chemo-therapy. Of the 62 patients involved in our study, 32 underwent neoadjuvant chemotherapy in combination with surgery, whereas the rest underwent neoadjuvant chemoimmunotherapy with surgery.Results: Investigation of T-cell-mediated and humoral immunity in patients with gastric cancer over the course of treatment found a reduction of the main indices of cell-mediated and humoral immunity in the patients who underwent standard therapy, which greatly caused a decline of antitumor, anti-infective, and antitoxic protection of the patients’ organisms.Conclusion: This study can contribute to the development of new therapies for gastric cancer as well as other types of cancer.

🔖

Bu Makaleye Atıf Yap

ZHANDOSSOV, O., KAUSSOVA, G., KOTEN, A. (2018). Combined treatment for gastric cancer: Immunological approach. Turkish Journal of Gastroenterology, Cilt: 29 - Sayı: 2, 151–156. https://ajindex.com/articles/410096

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Kawamoto M, Tanaka F, Mimori K, Inoue H, Kamohara Y and Mori M. Identification of HLA-A*0201/-A*2402-restricted CTL epi-tope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response. Oncol Rep 2011
  2. Wang W, Ji W, Hu H, Ma J, Li X and Mei W. Survivin promoter-reg-ulated oncolytic adenovirus with Hsp70 gene exerts effective anti-tumor efficacy in gastric cancer immunotherapy. Oncotarget 2010
  3. Whiteside T. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Can-cer Biol 2006
  4. [CrossRef] 22. Thorban S, Böttcher K, Etter M, Roder JD, Busch R and Siewert JR. Prognostic factors in gastric stump carcinoma. Ann Surg 2000
  5. [CrossRef] 21. Portnoy LM. Modern prospects for gastric cancer detection: liter-ature review, 1991. 20. Medvedev PS. Immunological status of gastric cancer patients at different stages of combined treatment
  6. Loginov AS, Potapova VB and Gudkova RB. Intercellular contacts of immunocompetent cells in the gastric mucosa. Immunology 1990
  7. Niccolai E, Taddei A, Prisco D and Amedei A. Gastric cancer and the epoch of immunotherapy approaches. World J Gastroenterol 2015
  8. [CrossRef] 17. Firth J, Carney R, Jerome L, Elliott R, French P and Yung AR. The effects and determinants of exercise participation in first-episode psychosis: a qualitative study. BMC Psych 2016
  9. [CrossRef] 16. On Amendments to the Decree of the Acting Minister of Health-care of the Republic of Kazakhstan
  10. Blinov LM and Kozhevnikov SN. Principles of early detection of malignant neoplasms. Probl Oncol 1990
  11. Kim JP, Kwon OJ, Oh ST and Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992
  12. [CrossRef] 13. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gas-troenterol 2006
  13. [CrossRef] 12. Matysiak-Budnik T and Mégraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006
  14. [CrossRef] 11. Brenner H, Rothenbacher D and Arndt V. Epidemiology of stom-ach cancer. Methods Mol Biol 2009
  15. [CrossRef] 10. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Glob-al cancer statistics. CA Cancer J Clin 2005
  16. [CrossRef] 9. Nurgaziyev KS, Baypeisov DM, Auezova ET, Zhylkaydarova AZ and Seysenbaye